Gruppo Oncologico del Nord-Ovest

🇮🇹Italy

Country: 🇮🇹Italy

Ownership: Private

Established: 1987-01-01

Employees: -

Market Cap: -

Website: http://gonogroup.org/

Clinical Trials

Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer

Phase 2

Recruiting

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: Pembrolizumab

First Posted Date: 2021-04-01

Last Posted Date: 2022-04-07

Lead Sponsor: Gruppo Oncologico del Nord-Ovest

Target Recruit Count: 30

Registration Number: NCT04825990

Locations: 🇮🇹
Asst Degli Spedali Civili Di Brescia, Brescia, Italy

TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.

Phase 2

Recruiting

Conditions: Gastric Cancer
Microsatellite Instability

Interventions: Drug: Durvalumab
Drug: Tremelimumab

First Posted Date: 2021-03-26

Last Posted Date: 2023-10-31

Lead Sponsor: Gruppo Oncologico del Nord-Ovest

Target Recruit Count: 31

Registration Number: NCT04817826

Locations: 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy

Tailored Sonidegib Schedule After Complete Response in BCC

Phase 2

Recruiting

Conditions: Locally Advanced Basal Cell Carcinoma

Interventions: Drug: Sonidegib

First Posted Date: 2021-03-19

Last Posted Date: 2022-08-04

Lead Sponsor: Gruppo Oncologico del Nord-Ovest

Target Recruit Count: 21

Registration Number: NCT04806646

Locations: 🇮🇹
Asst Degli Spedali Civili Di Brescia, Brescia, Italy

PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence

Phase 2

Recruiting

Conditions: Colorectal Cancer

Interventions: Drug: Panitumumab
Drug: Regorafenib

First Posted Date: 2021-03-08

Last Posted Date: 2023-11-27

Lead Sponsor: Gruppo Oncologico del Nord-Ovest

Target Recruit Count: 214

Registration Number: NCT04787341

Locations: 🇮🇹
U.O. Oncologia 2 Universitaria, Pisa, PI, Italy

Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCC

Phase 2

Recruiting

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Niraparib

First Posted Date: 2020-12-23

Last Posted Date: 2022-08-04

Lead Sponsor: Gruppo Oncologico del Nord-Ovest

Target Recruit Count: 49

Registration Number: NCT04681469

Locations: 🇮🇹
Asst Degli Spedali Civili Di Brescia, Brescia, Italy

Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients.

Phase 1

Recruiting

Conditions: Colorectal Cancer Metastatic

Interventions: Drug: Capecitabine
Drug: Bevacizumab
Drug: Trifluridine/Tipiracil

First Posted Date: 2020-09-25

Last Posted Date: 2024-02-22

Lead Sponsor: Gruppo Oncologico del Nord-Ovest

Target Recruit Count: 48

Registration Number: NCT04564898

Locations: 🇮🇹
Fondazione IRCCS Istituto Nazionale Tumori, Milano, MI, Italy
🇮🇹
Azienda Ospedaliero Universitaria Pisana, Pisa, PI, Italy

AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients

Phase 2

Active, not recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: 5Fluorouracil
Drug: L-leucovorin
Drug: Irinotecan
Drug: Oxaliplatin
Drug: Cetuximab
Drug: Avelumab

First Posted Date: 2020-08-14

Last Posted Date: 2023-09-13

Lead Sponsor: Gruppo Oncologico del Nord-Ovest

Target Recruit Count: 58

Registration Number: NCT04513951

Locations: 🇮🇹
U.O. Oncologia Medica 2 Universitaria - Azienda Ospedaliero-Universitaria Pisana Dipartimento di Ricerca Traslazionale e Nuove Tecnologie - University of Pisa, Pisa, Italy

Cetuximab + Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment (CARACAS)

Phase 2

Conditions: Squamous Cell Anal Carcinoma

Interventions: Drug: Avelumab
Drug: Cetuximab

First Posted Date: 2019-05-09

Last Posted Date: 2019-07-26

Lead Sponsor: Gruppo Oncologico del Nord-Ovest

Target Recruit Count: 54

Registration Number: NCT03944252

Locations: 🇮🇹
Istituto Oncologico Veneto IRCCS, Padova, Italy

Denosumab In Ebv Nasopharyngeal Carcinoma As A Model For RankMediated Immunologic Modulation Of Virus-Related Tumours

Phase 2

Conditions: Nasopharyngeal Carcinoma
EBV Related Carcinoma

Interventions: Drug: Denosumab Inj 120 MG/1.7ML
Drug: Chemotherapy as clinical standard of care

First Posted Date: 2019-04-23

Last Posted Date: 2020-02-17

Lead Sponsor: Gruppo Oncologico del Nord-Ovest

Target Recruit Count: 45

Registration Number: NCT03923842

Locations: 🇮🇹
ASST degli Spedali Civili di Brescia, Brescia, Italy
🇮🇹
Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy

Immunotherapy In Locally Advanced Rectal Cancer

Phase 2

Completed

Conditions: Colon Rectal Cancer

Interventions: Drug: Avelumab
Drug: Capecitabine
Radiation: EXTERNAL---BEAM IRRADIATION 50.4 GY

First Posted Date: 2019-02-26

Last Posted Date: 2023-10-19

Lead Sponsor: Gruppo Oncologico del Nord-Ovest

Target Recruit Count: 101

Registration Number: NCT03854799

Locations: 🇮🇹
Policlinico Gemelli, Rome, Italy

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy